Clinical stage oncology company Prescient Therapeutics (ASX:PTX) has boosted its intellectual property with the grant of two U.S. patents to protect its PTX-200 treatment for cancer.
Two Phase 1b/2 trials of PTX-200 are currently underway in the U.S. in patients with breast and ovarian cancers.
The first patent covers Prescient’s method for treating patients with tumours that overexpress AKT kinase, a key molecule in the oncogenic AKT signalling pathway.
Its second covers a proprietary method for identifying and treating a cancer patient with enhanced sensitivity to PTX-200 through a direct measurement of AKT levels in the patient’s tumour.
This patent further strengthens Prescient’s focus on “personalised medicine” whereby patients are selected based on their tumour blueprint and treated with a specific drug that targets such a blueprint, increasing the likelihood that a patient will respond to the drug.
PTX-200 is a small molecule that works by blocking the AKT pathway and inhibiting tumour growth.
High AKT expression is associated with a poor prognosis, resistance to chemotherapy and shortened survival times in a range of cancers.
Prescient had $1.04 million in cash as at 30th June 2015.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.